Guerbet Reports 2025 Revenue Decline Amid Raleigh Site Challenges — Guerbet SA

Event summary

Guerbet reported 2025 revenue of €786.4 million, down 3.5% at constant exchange rates and like-for-like, primarily due to a decline in French activity and issues at the Raleigh site.
EBITDA margin was 12.0%, at the high end of the adjusted range, but net income showed a loss of €112.7 million, including a non-recurring impairment of €86 million.
Free cash flow turned positive at €19.2 million, with net debt/EBITDA ratio at 4.0x, below the 4.8x ceiling set under the waiver obtained from lenders.
The Raleigh site's compliance issues with the FDA are expected to significantly impact 2026 revenue, profitability, and cash generation, with a probable risk of covenant breach by June 30, 2026.
No dividend will be distributed for the 2025 fiscal year as the company focuses on its transformation plan to improve sales momentum and competitiveness.

The big picture

Guerbet's 2025 results highlight the challenges posed by regulatory compliance issues at its Raleigh site, which are expected to exacerbate financial pressures in 2026. The company's strategic focus on operational efficiency and profitability improvement comes amid broader industry trends of cost discipline and regulatory scrutiny in the medical imaging sector. With a significant negative impact anticipated from the Raleigh situation, the company's ability to navigate these challenges will be critical for its long-term stability and growth.

What we're watching

Regulatory Compliance: Whether Guerbet can resolve the FDA compliance issues at the Raleigh site by the end of 2026 and return to normal operations.
Financial Stability: The likelihood of obtaining a waiver from lenders to avoid a covenant breach and the potential impact on the company's financial structure.
Transformation Plan: The effectiveness of Guerbet's transformation plan in restoring long-term profitability and sales momentum, with full effects expected by 2027.